Stockscreener 앱 받기
0.00
100.00%
-1.14
전일 마감가:
$1.14
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$N/A
수익:
$3.13M
순이익/손실:
$-40.29M
주가수익비율:
0.00
EPS:
-3.2
순현금흐름:
$-33.08M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
+427.32%
1년 성능:
+221.67%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$1.15
Trevena Inc Stock (TRVN) Company Profile
TRVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVN
Trevena Inc
|
0.00 | 0 | 3.13M | -40.29M | -33.08M | -3.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.65 | 96.11B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.13 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.14 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.15 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.52 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevena Inc Stock (TRVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-15 | 개시 | Oppenheimer | Perform |
| 2020-09-14 | 개시 | Guggenheim | Buy |
| 2020-08-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-05-31 | 재개 | H.C. Wainwright | Buy |
| 2018-11-05 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-10-12 | 다운그레이드 | Needham | Buy → Hold |
| 2018-10-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2017-11-08 | 재확인 | Needham | Buy |
| 2017-10-16 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2017-10-12 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-08 | 재확인 | Needham | Buy |
| 2017-02-23 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-22 | 재확인 | FBR & Co. | Outperform |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2017-01-09 | 개시 | H.C. Wainwright | Buy |
| 2017-01-05 | 개시 | Oppenheimer | Outperform |
| 2016-05-17 | 재확인 | FBR Capital | Outperform |
| 2016-05-17 | 재확인 | Needham | Buy |
| 2016-03-29 | 개시 | FBR Capital | Outperform |
| 2015-09-01 | 재확인 | Wedbush | Outperform |
| 2015-08-03 | 개시 | Brean Capital | Buy |
모두보기
Trevena Inc 주식(TRVN)의 최신 뉴스
BRIEF-Amara Holdings To Be Delisted From SGX-St Mainboard - Yahoo.co
Aegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the Board - GlobeNewswire
Aegle Therapeutics Names Scott Braunstein, M.D. as Chairman of the Board - citybiz
Is Trevena, Inc. overvalued or undervalued? - MarketsMojo
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors - GlobeNewswire
Trevena (NASDAQ:TRVN) Stock Price Crosses Below 200-Day Moving Average – Here’s What Happened - Defense World
TREVENA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Trevena, Inc. To Contact The Firm - ACCESS Newswire
Acute Pain Drug Pipeline Analysis: Market Overview, Trends, and Future Growth (2034) - openPR.com
Trevena to Present at the H.C. Wainwright Global Investment Conference - The Globe and Mail
Opioid Drugs Market in 2025-2032 Detailed Study Analysis with - openPR.com
Financial Comparison: Adicet Bio (NASDAQ:ACET) & Trevena (NASDAQ:TRVN) - Defense World
Behind the Booth at InfoComm 2025: An Interview With tvONE’s Mark Trevena - rAVe [PUBS]
Trevena (TRVN) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws; Investors Who Suffered Losses Exceeding $50,000 Encouraged to Contact the Firm - ACCESS Newswire
COVID-19 Therapeutics Market Current Scenario with Future Aspect Analysis - openPR.com
Opioid Drugs Market: Investment Analysis & Growth Opportunity - openPR.com
Highest-Paid CEOs2024 - AFL-CIO
Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com - Defense World
Biopharma Dealmaking Quarterly Statistics, Q2 2013 - insights.citeline.com
Block & Leviton Files Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm - ACCESS Newswire
Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com - Defense World
Aviation Co. Says Workers' Class Action Too Broad - Law360
Block & Leviton Reminds Shareholders of Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm - ACCESS Newswire
North American Morning Briefing : Stock Futures -2- - MarketScreener
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN) - Defense World
Trevena (NASDAQ:TRVN) Stock Crosses Below 200 Day Moving Average – Time to Sell? - Defense World
Opioid Drugs Market Detailed In New Research Report 2025-2032 | - openPR.com
Trevena Delays Yearly Report Filing - TipRanks
Trevena (TRVN) Expected to Announce Quarterly Earnings on Monday - Defense World
Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc.; Mountain Crest Acquisition Corp. V - The Manila Times
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatm - The Manila Times
Global Post Operative Pain Management Market Advancements Highlighted by Forecast: Key Growth Drivers, Tren... - WhaTech
Ten option delistings on March 24th - TipRanks
Trevena (NASDAQ:TRVN) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell? - Defense World
StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN) - The AM Reporter
Opioid Drugs Market to Witness Remarkable Growth with Johnson & Johnson, Endo International plc - openPR
Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com - Defense World
Trevena, Inc. to Host Earnings Call - ACCESS Newswire
Trevena (NASDAQ:TRVN) Now Covered by StockNews.com - Defense World
Opioid Drugs Market Growth, Demand Trends, Size & Competitive - openPR
Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com - Defense World
Promising Automotive Stocks To Keep An Eye On – February 04th - ETF Daily News
Trevena Announces Board and Executive ChangesOn January 31, 2025, Trevena, Inc. (NASDAQ:TRVN) filed a Form 8-K with the Securities and Exchange Commission, detailing significant departures and appointments within the company.In line with ongoin - Defense World
Trevena Inc (TRVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.10%
0.21%
자본화:
|
볼륨(24시간):